Anticonvulsant

Global Epilepsy Drugs Market 2018-2022: Use of Genetics as Therapeutics and Diagnostic Modality Gaining Momentum

Retrieved on: 
Dienstag, Oktober 2, 2018
Epilepsy, Anticonvulsant

The "Global Epilepsy Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Epilepsy Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
  • The Global Epilepsy Drugs Market to grow at a CAGR of 7.19% during the period 2018-2022.
  • Global Epilepsy Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts.
  • The global epilepsy drugs market has several clinical and non-clinical unmet needs, such as low safety profile of AEDs especially among women.

First Prescription Formulation of Cannabidiol (CBD) Approved for Lennox-Gastaut Syndrome

Retrieved on: 
Dienstag, Juni 26, 2018
Epilepsy, Medicine, Neurology, Rare diseases, Lennox–Gastaut syndrome, Atonic seizure, Dravet syndrome, Lennox, Cannabidiol, Epileptic seizure, LGS, Anticonvulsant

EPIDIOLEX is the first prescription pharmaceutical formulation of highly purified CBD and the first in its class of anti-epileptic drugs.

Key Points: 
  • EPIDIOLEX is the first prescription pharmaceutical formulation of highly purified CBD and the first in its class of anti-epileptic drugs.
  • "Today's announcement gives individuals with Lennox-Gastaut Syndrome and their families much-needed hope," says LGS Foundation Executive Director Christina SanInocencio.
  • [i]
    Along with the FDA's approval for EPIDIOLEX for seizures associated with Lennox-Gastaut Syndrome, the approval is also indicated for another form of rare epilepsy that begins in childhood called Dravet Syndrome.
  • Effect of Cannabidiol on Drop Seizures in the LennoxGastaut Syndrome.

Cerebral Therapeutics Raises Series A Financing to Advance Clinical-Stage Drug-Device Combination Therapy for Adult Refractory Epilepsy

Retrieved on: 
Mittwoch, Juni 20, 2018
Epilepsy, Anticonvulsant

Cerebral Therapeutics is currently exploring direct intracerebroventricular (ICV) administration of a proprietary formulation of an anti-epileptic drug to potentially enhance efficacy and reduce toxicity in adult patients with refractory epilepsy.

Key Points: 
  • Cerebral Therapeutics is currently exploring direct intracerebroventricular (ICV) administration of a proprietary formulation of an anti-epileptic drug to potentially enhance efficacy and reduce toxicity in adult patients with refractory epilepsy.
  • "I am excited about the significant capability our new investors and board members bring to Cerebral Therapeutics," said Dan Abrams, M.D., CEO of Cerebral Therapeutics.
  • Cerebral Therapeutics is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy.
  • Cerebral Therapeutics' infusion therapy may offer a more efficacious and reliable approach to treating neurological diseases for which oral and I.V.

Eisai Receives FDA Priority Review Designation for FYCOMPA® (perampanel) CIII Pediatric Indications Supplemental New Drug Application (sNDA)

Retrieved on: 
Mittwoch, Mai 30, 2018
Health, Food and Drug Administration, United States Public Health Service, Anticonvulsant, Priority review, Medicine, Eisai

To date, more than 100,000 patients have been treated with FYCOMPA worldwide across all indications.

Key Points: 
  • To date, more than 100,000 patients have been treated with FYCOMPA worldwide across all indications.
  • "The FDA's Priority Review designation for this sNDA underscores the urgent need for more treatment options like FYCOMPA in the pediatric population," said Lynn Kramer, MD, Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai.
  • FYCOMPA has been designated by the U.S. Drug Enforcement Administration as a federally-controlled substance (CIII).
  • Physicians are advised to recommend that pregnant patients taking FYCOMPA enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry.

UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen

Retrieved on: 
Freitag, April 20, 2018
Epilepsy, UCB, Anticonvulsant, GABAA receptor positive allosteric modulators, Midazolam, Medicine, Chemistry, Health

Acquisition of USL261 complements UCB's already successful anti-epilepsy drug portfolio, enhancing the company's position as a global leader in epilepsy.

Key Points: 
  • Acquisition of USL261 complements UCB's already successful anti-epilepsy drug portfolio, enhancing the company's position as a global leader in epilepsy.
  • As a global leader in epilepsy, with a pioneering commitment to improving patient value, UCB was the natural choice to progress the development journey of midazolam nasal spray," said Bill Pullman, Chief Scientific Officer and President, Proximagen.
  • UCB has a rich heritage in epilepsy with over 20 years of experience in the research and development of antiepileptic drugs.
  • At UCB, we are inspired by patients, and driven by science in our commitment to support patients with epilepsy.